Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Larissa A. Korde et al.|Unknown|2023Cited by 0
Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Megan Othus et al.|Unknown|2023Cited by 0
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Nikhil I. Khushalani et al.|Unknown|2023Cited by 0
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Megan Othus et al.|Unknown|2023Cited by 0